Canadian model projects 22,200 fewer hospitalisations from semaglutide by 2029

The wire

1. 01A multi-indication model covering 1,000,000 treated Canadians with type 2 diabetes, cardiovascular disease, MASH or CKD projected 8,400 fewer cardiovascular events, 1,100 fewer cardiovascular deaths and 235,000 fewer obesity cases by 2029.
2. 02Payers and clinicians arguing semaglutide value beyond narrow healthcare budgets now have a published societal-perspective estimate, including 330kt CO2e avoided and CAD 2.0 billion in resource-use savings.
3. 03This is a simulation, not observed outcomes; results were most sensitive to baseline utility values, productivity used a US-based model, and the author list includes Novo Nordisk affiliation. The model also projected 21,200 gastrointestinal adverse events.

From the source

Estimating the Wider Societal Impact of Semaglutide Across Multiple Indications in Canada: an Economic Evaluation

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026 Sep 29 · Husereau D, Evans M, Hahn-Pedersen JH et al.